Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Biotechnology Business
Reports from Biogen Idec, Inc. describe recent advances in biotechnology business
June 9th, 2009
"Therapeutic antibodies directed against the type 1 insulin-like growth factor receptor (IGF-1R) have recently gained significant momentum in the clinic because of preliminary data generated in human patients with cancer. These antibodies inhibit ligand-mediated activation of IGF-1R and the resulting downstream signaling cascade," researchers in the United States report. "Here we generated a panel of antibodies against IGF-1R and screened them for their ability to block the binding of both IGF-1 and IGF-2 at escalating ligand concentrations (> 1 mc M) to investigate allosteric versus competitive blocking mechanisms. Four distinct inhibitory classes were found as...
Source: Cancer Weekly (2009-06-09)
|
